Press Releases

Date	Title and Summary	View
Dec 19, 2019	MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA ROCKVILLE, MD , Dec. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company has submitted a
Dec 11, 2019	MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium Biologics License Application (BLA) submission to FDA expected before the end of 2019 Rockville, MD , Dec. 11, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based
Dec 09, 2019	MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting Conference call scheduled for today at 8:00 p.m. ET Rockville, MD , Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Dec 02, 2019	MacroGenics to Participate in the Evercore ISI HealthCONx Conference Rockville, MD , Dec. 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Nov 07, 2019	MacroGenics to Participate in Upcoming Investor Conferences Rockville, MD , Nov. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Nov 06, 2019	MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Nov 06, 2019	MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019 ROCKVILLE, MD , Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the clinical and preclinical abstracts
Oct 30, 2019	MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call Rockville, MD , Oct. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Oct 25, 2019	MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer Rockville, MD , Oct. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed
Oct 22, 2019	MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer ROCKVILLE, MD , Oct. 22, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced topline results from the second
Sep 30, 2019	MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress ROCKVILLE, MD , Sept. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a Phase 2 study
Sep 26, 2019	MacroGenics to Participate in Cantor Global Healthcare Conference ROCKVILLE, MD , Sept. 26, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Aug 29, 2019	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , Aug. 29, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Aug 08, 2019	MacroGenics to Participate in Upcoming Investor Conferences Rockville, MD , Aug. 08, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Jul 31, 2019	MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md. , July 31, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Jul 24, 2019	MacroGenics Announces Date of Second Quarter 2019 Financial Results Conference Call Rockville, Md. , July 24, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Jul 17, 2019	MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia Enrollment of Phase 1 monotherapy expansion cohort completed; presentation of data expected 2H2019 End of Phase 1 meeting requested with FDA to discuss program and future development plans Initiation of enrollment of combination study with anti-PD-1 is imminent MacroGenics will regain full global
Jul 10, 2019	MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China ROCKVILLE, MD , and SHANGHAI, China , July 10, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, and I-Mab Biopharma (I-Mab), a
May 30, 2019	MacroGenics to Participate in Jefferies Healthcare Conference Rockville, MD , May 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
May 28, 2019	MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO Rockville, MD , May 28, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call and audio
May 15, 2019	MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy) Oral abstract will be presented at American Society of Clinical Oncology ( ASCO ) Annual Meeting on June 4, 2019 at 9:45 a.m.
May 01, 2019	MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md. , May 01, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Apr 24, 2019	MacroGenics Announces Date of First Quarter 2019 Financial Results Conference Call ROCKVILLE, MD , April 24, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Apr 03, 2019	MacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019 ROCKVILLE, MD , April 03, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the presentation of preclinical and
Apr 02, 2019	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , April 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will